2014
Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2011
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. Alcohol 2011, 46: 121-131. PMID: 21925828, PMCID: PMC3266454, DOI: 10.1016/j.alcohol.2011.08.008.Peer-Reviewed Original ResearchConceptsDaily heavy drinkersFrequent heavy drinkersHeavy drinkersHeavy drinkingDrinking outcomesAlcohol-dependent patientsBehavioral intervention studyHeavy drinking trajectoriesSummary drinking measuresBaseline characteristicsActive treatmentSevere baselineCombined PharmacotherapiesWorse outcomesPharmacological interventionsCOMBINE StudyIntervention studiesPatientsTreatment factorsDrinkersOutcomesTrajectory membershipDrinking measuresTreatment effectsDrinkingCognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders
Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, Cohen JD, Geyer M, Gollub R, Green MF, Jaeger J, Krystal JH, Moore H, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders. Biological Psychiatry 2011, 70: 7-12. PMID: 21529781, PMCID: PMC3116022, DOI: 10.1016/j.biopsych.2011.01.041.Peer-Reviewed Original ResearchConceptsCognitive Neuroscience Treatment ResearchTreatment researchCognitive neuroscienceTreatment developmentFunctional magnetic resonance imagingSchizophrenia (MATRICS) initiativeSchizophrenia IIPotential confoundsImpaired cognitionCognitionNeural systemsNeural activityPsychometric propertiesMental healthBrain functionTranscranial magnetic simulationNeuroscienceTreatment effectsSchizophreniaMulticenter phase IITranslational researchImproved animal modelsPragmatic issuesBiological psychiatryMagnetic resonance imaging
2003
Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, Krystal JH. Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. JAMA Psychiatry 2003, 60: 49-56. PMID: 12511172, DOI: 10.1001/archpsyc.60.1.49.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationMedication-resistant auditory hallucinationsTranscranial magnetic stimulationLeft temporoparietal cortexAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal cortexOpen-label trialMotor thresholdAntipsychotic medicationSustained reductionBrain areasSchizoaffective disorderCortical activationPossible treatmentNeuropsychological impairmentNeuropsychological assessmentPatientsAdditional studiesCortexStimulationTrialsHallucinationsTreatment effects
2000
Antidepressant effects of ketamine in depressed patients
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D, Krystal J. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47: 351-354. PMID: 10686270, DOI: 10.1016/s0006-3223(99)00230-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepressive Disorder, MajorDose-Response Relationship, DrugDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamic AcidHumansInjections, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSeverity of Illness IndexConceptsMajor depressionN-methyl-D-aspartate receptor antagonistBrain glutamate systemDouble-blind trialDouble-blind conditionsTreatment of depressionMechanism of actionPlacebo infusionAntidepressant effectsIntravenous treatmentSingle doseReceptor antagonistDepressed patientsGlutamate systemDepressive symptomsPreclinical researchKetamine hydrochlorideDepressionPotential roleTest dayTreatment effectsPatientsKetamineSaline solutionTreatment